Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001847507 | SCV002104934 | likely benign | Hereditary spastic paraplegia | 2018-01-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003328486 | SCV004035211 | uncertain significance | not provided | 2017-03-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003365459 | SCV004069925 | uncertain significance | Inborn genetic diseases | 2023-07-12 | criteria provided, single submitter | clinical testing | The c.1217G>A (p.R406Q) alteration is located in exon 6 (coding exon 6) of the RTN2 gene. This alteration results from a G to A substitution at nucleotide position 1217, causing the arginine (R) at amino acid position 406 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |